kabutan

Modalis Therapeutics Corporation(4883) Summary

4883
TSE Growth
Modalis Therapeutics Corporation
58
JPY
0
(0.00%)
Mar 13, 3:30 pm JST
0.36
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
58.3
Mar 13, 11:56 pm JST
Summary Chart Historical News Financial Result
PER
PBR
1.84
Yield
ー%
Margin Trading Ratio
5,129.87
Stock Price
Mar 13, 2026
Opening Mar 13, 9:00 am
58 JPY 0.36 USD
Previous Close Mar 12
58 JPY 0.36 USD
High Mar 13, 9:00 am
58 JPY 0.36 USD
Low Mar 13, 9:32 am
57 JPY 0.35 USD
Volume
258,600
Trading Value
0.02B JPY 0.09M USD
VWAP
57.67 JPY 0.36 USD
Minimum Trading Value
5,800 JPY 36 USD
Market Cap
5.07B JPY 0.03B USD
Number of Trades
48
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
Mid
1-Year Average
369
1-Year High Jun 9, 2025
9,562
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 0 10,206,600
Feb 27, 2026 0 10,322,700
Feb 20, 2026 0 9,902,100
Feb 13, 2026 0 9,792,800
Feb 6, 2026 0 9,706,600
Company Profile
Modalis Therapeutics Corporation conducts research and development of gene therapy drugs using its proprietary genome editing platform. The company has a base in the United States.
Sector
Pharmaceuticals
Modalis Therapeutics Corporation utilizes its proprietary genome editing platform, centered on CRISPR-GNDM technology, to research and develop gene therapy drugs. This technology functions as a "gene switch" that can control gene expression without cutting DNA, offering higher safety compared to conventional genome editing methods. The company aims to address genetic diseases, which are often in the rare disease category and inefficient to develop using traditional drug discovery approaches, by leveraging its technological prowess. Modalis employs a hybrid business model, combining partnerships with pharmaceutical companies ("collaboration model") and in-house development ("proprietary model"). The collaboration model aims for early revenue generation, while the proprietary model targets larger future revenues. The company has several ongoing development pipelines and aims to secure licensing agreements at specific stages of development.